Sydney, June 8, 2026, 05:04 AEST
Cochlear Limited enters the holiday week at A$100.45, Friday’s last price, after shares jumped A$5.35, or 5.63%. It was one of the stronger S&P/ASX 200 performers while the index dropped 0.7% to 8,625.1. CSL, in the broader ASX healthcare group, finished up 5.75%.
ASX cash trading is shut Monday for the King’s Birthday holiday on June 8. The next session opens Tuesday, giving investors a first look at whether Friday’s lift was more than just short-covering or bargain hunting.
Cochlear’s rebound didn’t do much. The stock is flat for the week and sits about 69% below its 52-week high of A$319.42, Intelligent Investor data shows.
Cochlear shares are still feeling the impact of the April profit warning. The company lowered its FY26 underlying net profit guidance to A$290 million-A$330 million, down from its earlier A$435 million-A$460 million range. Cochlear also expects second-half sales growth of 2%-6% in constant currency, which excludes currency effects.
Cochlear pointed to weaker implant demand in developed markets, tight hospital capacity, fewer referrals from the hearing-aid channel, and lower premium sales in China. The company also cited uncertainty tied to the Middle East. CEO Dig Howitt said in April that “market share has been improving” and “the clinical need for cochlear implants continues to grow.”
Cochlear shares plunged almost 41% in a single day when the company cut its annual earnings outlook, blaming soft trading and concerns over the Middle East war, Reuters reported. Friday’s bounce is an attempt to recover some of that drop.
Morningstar analyst Lochlan Halloway, CFA, pushed back on the bearish mood in a June 5 note. He stuck to the A$110 fair value target and called the shares “slightly undervalued.” Halloway said Morningstar is “more optimistic than the market” on implant demand. He named Cochlear as the top cochlear implant company, with about 60% of the world market. Morningstar
Bulls are looking at Nexa’s product launch, demand in emerging markets, and the adults-and-seniors group. A cochlear implant is surgically implanted to skip over damaged ear sections and send signals to the auditory nerve; unlike hearing aids, which just make sound louder.
The risks are still clear. If consumer caution in the U.S., hospital delays in Europe, trouble with deliveries or payments in the Middle East, or price pressure in China hang around, Friday’s gain might not last. Morningstar named low-cost rival Nurotron as another price risk outside China.
Cochlear is facing the A$100 level as the ASX gets set to open for the week. The next scheduled company report is further out, with Market Index putting Aug. 14 as the likely date for Cochlear’s preliminary and annual numbers.
